Materialise (MTLS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 May, 2026Executive summary
Divested RapidFit and Eyewear businesses to management teams, retaining a minority stake in Eyewear and transferring all employees, sharpening focus on core activities.
Expanded medical portfolio with custom-made PEEK implants and launched OrthoView 3D Hip for advanced surgical planning.
Introduced CO-AM Professional, a cloud-based software for 3D printing, and deepened partnership with HP for the MJF 1200 printer.
Published first annual report post-Euronext listing and completed CSRD sustainability reporting, highlighting sustainability progress.
Achieved significant sustainability milestones, including a reduction of over 1,500 tons of CO2 and increased use of renewable energy.
Financial highlights
Q1 2026 revenue was EUR 66.3 million, stable year-over-year despite FX headwinds.
Gross profit rose to EUR 37.9 million, with gross margin expanding to 57.2% from 55.3% last year.
Adjusted EBIT improved to EUR 2.5 million (3.7% margin), and net profit reached EUR 1.8 million (EUR 0.03 per share).
Free cash flow was EUR 5.7 million, increasing net cash position to EUR 72.8 million.
Cash and cash equivalents stood at EUR 133 million, with gross debt reduced to EUR 60.1 million.
Outlook and guidance
Reaffirmed full-year 2026 revenue guidance of EUR 273–283 million and adjusted EBIT of EUR 10–12 million, despite divestments.
Expect continued macroeconomic and geopolitical uncertainty but anticipate improved operational performance and profitable growth.
Manufacturing EBITDA expected to be positive for full year 2026.
Latest events from Materialise
- Medical segment drove 4.3% revenue growth, but profits fell; 2025 guidance unchanged.MTLS
Q1 202517 Mar 2026 - Q4 revenue up 6.8%, Medical segment leads, 2026 EBIT guided at EUR 10–12 million.MTLS
Q4 202519 Feb 2026 - Record Q2 revenue and profit, led by Medical growth and strategic medical technology expansion.MTLS
Q2 20242 Feb 2026 - Q3 2024 revenue up 14.2% to €68.7M, led by Medical; full-year outlook reaffirmed.MTLS
Q3 202418 Jan 2026 - Medical growth drove profit gains, but Manufacturing and Software faced headwinds in 2024.MTLS
Q4 202423 Dec 2025 - Medical segment growth offsets overall revenue decline; cost control sustains profitability.MTLS
Q2 202516 Nov 2025 - Q3 2025 revenue fell 3.5% as Medical growth offset declines in Manufacturing and Software.MTLS
Q3 202529 Oct 2025 - 2024 revenue rose 4.2% to 266.8 mEUR, with Medical segment leading growth.MTLS
Corporate Presentation6 Jun 2025